英国连锁药店博姿(Boots)宣布将开始提供医用大麻处方服务,成为英国首家涉足该领域的高街药房 1。这项名为“SureLeaf”的在线服务主要面向英国境内25岁及以上、患有慢性疼痛、焦虑或失眠等符合条件疾病的患者 1。为确保用药安全,所有处方需经过多学科临床团队独立审查,且患者须先尝试传统疗法无效 1。
医用大麻在英国于2018年合法化 1。尽管澳大利亚和英国大学的研究发现医用大麻对焦虑、厌食症等疗效证据极少,但博姿强调其严格的临床审查机制 1。Jamie Kerruish表示:“Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief.” 1
此外,博姿还与诺丁汉大学开展合作研究项目,旨在评估治疗效果及处方规范 1。Dr David Gwynne指出:“Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.” 1
Boots has announced it will launch a medical cannabis prescribing service, becoming the first high street pharmacy chain in the United Kingdom to enter this field 1. The new online initiative, named SureLeaf, is designed for patients aged 25 and older who suffer from qualifying conditions such as chronic pain, anxiety, or insomnia 1.
To ensure patient safety, prescriptions are subject to independent review by a multidisciplinary clinical team. Eligibility also requires that patients have previously tried traditional treatments without adequate symptom relief 1. Jamie Kerruish stated, "Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief" 1. Dr David Gwynne emphasized caution, noting, "Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis" 1.
While medical cannabis was legalized in the UK in 2018, research involving Australian and British universities suggests there is limited evidence supporting its efficacy for conditions like anxiety and anorexia 1. As part of the rollout, Boots is partnering with the University of Nottingham on a research project aimed at evaluating treatment outcomes and establishing prescription standards 1.
评论
还没有评论,欢迎留下第一条。